uniQure (QURE) Competitors $5.70 -0.12 (-2.06%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends QURE vs. APLT, AVDL, ZYME, SEPN, COGT, BCAX, BCYC, COLL, PAHC, and IMTXShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Applied Therapeutics (APLT), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), Phibro Animal Health (PAHC), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Applied Therapeutics Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics Bicycle Therapeutics Collegium Pharmaceutical Phibro Animal Health Immatics Applied Therapeutics (NASDAQ:APLT) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Does the media favor APLT or QURE? In the previous week, Applied Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 1 mentions for Applied Therapeutics and 0 mentions for uniQure. Applied Therapeutics' average media sentiment score of 0.65 beat uniQure's score of -1.00 indicating that Applied Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Applied Therapeutics Positive uniQure Negative Is APLT or QURE more profitable? Applied Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -837.80%. uniQure's return on equity of -188.82% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -260.75% -76.04% uniQure -837.80%-188.82%-32.17% Which has preferable valuation and earnings, APLT or QURE? Applied Therapeutics has higher earnings, but lower revenue than uniQure. Applied Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics$9.99M109.84-$119.76M-$1.61-5.86uniQure$15.84M17.54-$308.48M-$4.96-1.15 Does the MarketBeat Community favor APLT or QURE? uniQure received 568 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 70.65% of users gave uniQure an outperform vote while only 58.33% of users gave Applied Therapeutics an outperform vote. CompanyUnderperformOutperformApplied TherapeuticsOutperform Votes7758.33% Underperform Votes5541.67% uniQureOutperform Votes64570.65% Underperform Votes26829.35% Do analysts rate APLT or QURE? Applied Therapeutics currently has a consensus price target of $12.50, indicating a potential upside of 32.56%. uniQure has a consensus price target of $17.00, indicating a potential upside of 198.25%. Given uniQure's higher possible upside, analysts plainly believe uniQure is more favorable than Applied Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17uniQure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more risk & volatility, APLT or QURE? Applied Therapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Do insiders & institutionals have more ownership in APLT or QURE? 98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 8.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryApplied Therapeutics beats uniQure on 12 of the 19 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$277.82M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-1.1510.78135.4117.82Price / Sales17.54243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book1.315.474.674.68Net Income-$308.48M$153.61M$119.07M$226.08M7 Day Performance-15.56%-2.00%-1.83%-1.04%1 Month Performance-13.64%-7.46%-3.60%1.04%1 Year Performance-15.30%31.82%31.66%26.28% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure3.0892 of 5 stars$5.70-2.1%$17.00+198.2%-18.2%$283.68M$15.84M-1.15500Negative NewsAPLTApplied Therapeutics4.3431 of 5 stars$9.43+5.6%$12.50+32.6%+373.9%$1.10B$9.99M-5.8330AVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$138.16M-13.61154Short Interest ↓ZYMEZymeworks2.8655 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst RevisionBCYCBicycle Therapeutics2.8495 of 5 stars$20.36-0.6%$40.13+97.1%+49.4%$968.12M$26.98M-6.19240Analyst RevisionCOLLCollegium Pharmaceutical3.9744 of 5 stars$30.00+0.8%$42.60+42.0%+17.2%$967.50M$566.77M12.93210PAHCPhibro Animal Health4.2227 of 5 stars$23.39-1.5%$16.50-29.5%+123.4%$961.95M$1.02B54.401,940Analyst DowngradeIMTXImmatics2.0136 of 5 stars$7.80-0.1%$16.67+113.7%-9.2%$930.98M$70.87M-8.76260Analyst ForecastNews Coverage Related Companies and Tools Related Companies APLT Alternatives AVDL Alternatives ZYME Alternatives SEPN Alternatives COGT Alternatives BCAX Alternatives BCYC Alternatives COLL Alternatives PAHC Alternatives IMTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QURE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
